Rentosertib: discovery, trials and ageing clocks

Rentosertib is an investigational TNIK inhibitor developed for idiopathic pulmonary fibrosis. By 4 October 2026, its public record includes discovery papers, a randomised Phase 2a trial, a proteomic clock analysis and a company announcement of first dosing in Phase III.

The discovery record describes AI's contribution to choosing a target and developing a molecule. The clinical record examines people with a defined lung disease. The ageing analysis asks what their blood proteins reveal. Treating the whole sequence as one proof of human rejuvenation would lose the distinctions between those experiments.

What AI contributed

The 2024 discovery paper describes a predictive AI approach to identify TNIK as an anti-fibrotic target and generative methods used during molecule development. The team then synthesised candidates and examined their activity, selectivity and drug-related properties. This is programme-specific evidence of AI use.

The published account reports about eighteen months between target discovery and preclinical candidate nomination. That interval has a defined end point. It does not include all subsequent clinical development, and the paper does not provide a matched experiment in which an otherwise identical team developed the programme without AI.

Early leads had problems including clearance, solubility and interactions with drug-metabolising enzymes. Optimisation addressed those properties before nomination.

The medicinal-chemistry paper documents the inhibitor series and its development. All authors disclose employment at Insilico. Company participation does not invalidate the experiments; it should remain visible when readers assess the interpretation.

The clinical question

The Phase 2a paper, published in June 2025, describes 71 participants with IPF, randomised among three active regimens and placebo over twelve weeks. Its primary endpoint concerned treatment-emergent adverse events. Lung-function measurements were secondary endpoints.

The paper reported a favourable forced vital capacity signal in the highest daily-dose group, with uncertainty around the estimate. It also reported discontinuations, including events related to liver toxicity or diarrhoea. Those findings support further testing; the study's size and duration leave substantial uncertainty about longer-term benefit and harms.

FVC measures the volume forcibly exhaled after a full inhalation. It addresses lung function in this population. The trial did not measure human lifespan or demonstrate that unaffected organs had become younger.

Calling the programme an AI discovery success and calling the molecule an effective medicine require different evidence. The molecule can demonstrate that an AI-assisted process produced a testable candidate even if a later trial finds insufficient benefit.

Where the ageing claim enters

The September 2026 paper applied six proteomic clocks to samples from 42 participants in the same Phase 2a study. The clocks reported younger predicted profiles in treated participants, with differences between regimens and time points.

Six models are not six independent clinical trials. They analyse a shared biological sample, and some model assumptions or inputs overlap. Agreement adds information while leaving the population and observation period unchanged.

The authors acknowledge that this IPF cohort cannot fully separate an effect on ageing from the drug's effects on the disease. Their pathway analyses examine that problem indirectly; they do not remove it.

The strongest lung-function signal and the broadest clock response occurred in different regimens. This makes it especially unhelpful to substitute “age reversal” for the actual endpoints.

The analysis is an exploratory result about circulating proteins. Confirmation would require suitable prospective studies, with prespecified analyses and outcomes that test the broader claim.

The next trial asks a longer question

On 10 September 2026, Insilico announced the first participant dosed in GENESIS-IPF-3, identified as NCT07687459. The company describes a randomised, blinded, placebo-controlled study lasting 52 weeks, with 320 participants planned across China.

Its stated primary endpoint is the annual rate of FVC decline. The longer observation and larger population address questions left open by Phase 2a. They do not yet provide results. The company states that rentosertib remains investigational.

The programme is therefore at an active test of sustained lung-disease benefit. Its AI discovery record, early clinical findings and ageing-clock analysis should each retain their own assessment. A Phase III result would need to be read against the protocol and actual outcomes, including harms and missing data.